BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO) priced its initial public offering on Jun 28, 2019 at $17.00 per share, above its $14.00–$16.00 range, raising $348.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.05B. J.P. Morgan was lead-left underwriter, joined by Goldman Sachs, Jefferies and Leerink Partners and others. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

BridgeBio Pharma, Inc. is a drug development company, founded in 2015, working on medicines for Mendelian diseases caused by single-gene defects and for cancers with clear genetic drivers. Its pipeline has over 15 programs, including four candidates in clinical trials, two of them in Phase 3.

Status

IPO

Ticker

BBIO

Exchange

Nasdaq Global Select

Priced

Jun 28, 2019

IPO price

$17.00

Price range

$14.00–$16.00

Raised

$348.5M

Market cap at IPO price

$2.05B

First filed

May 24, 2019

Underwriters

J.P. Morgan, Goldman Sachs, Jefferies, Leerink Partners, KKR, Piper Sandler, Mizuho, BMO Capital Markets and Raymond James

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.